Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure (Q43636274)

25 November 2017

Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure (English)

1 reference

25 November 2017

heart rate variability

0 references

0 references

1 reference

congestive heart failure

1 reference

3

1 reference

25 November 2017

Yee KM

1

1 reference

PubMed ID

11401114

25 November 2017

Pringle SD

series ordinal

2

1 reference

PubMed ID

11401114

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

Journal of the American College of Cardiology

25 November 2017

1 reference

25 November 2017

37

1 reference

25 November 2017

7

1 reference

25 November 2017

1800-1807

1 reference

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Aldosterone reduces baroreceptor discharge in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Aldosterone blunts the baroreflex response in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Diurnal variations of plasma aldosterone in supine man: relationship to plasma renin activity and plasma cortisol

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Spontaneous Variability and Circadian Distribution of Ectopic Activity in Patients With Malignant Ventricular Arrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Circadian variation in the frequency of onset of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Timing of sudden death in patients with heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

QT dispersion and sudden unexpected death in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Determination of norepinephrine apparent release rate and clearance in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Twenty-four-hour spectral analysis of heart rate variability in congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Decreased spontaneous heart rate variability in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Assessment of autonomic tone over a 24-hour period in patients with congestive heart failure: relation between mean heart rate and measures of heart rate variability

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Digoxin reduces cardiac sympathetic activity in severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

QT interval dispersion in healthy subjects and survivors of sudden cardiac death: circadian variation in a twenty-four-hour assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Circadian variation of QT interval dispersion: correlation with heart rate variability.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

QT interval prolongation as predictor of sudden death in patients with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Mechanisms of ventricular arrhythmias in cardiac failure and hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Reduction in QT dispersion by sotalol following myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Improvement of vagal tone by ACE inhibition: a mechanism of cardioprotection in patients with mild-to-moderate heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Relation of Electrolyte Disturbances to Cardiac Arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Observations in experimental magnesium depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Magnesium therapy for torsades de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Characteristics of transient outward current in human ventricular myocytes from patients with terminal heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

Normalization of acquired QT prolongation in humans by intravenous potassium.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901243-8

7 January 2021

10.1016/S0735-1097(01)01243-8

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

11401114